65
Participants
Start Date
May 31, 2009
Primary Completion Date
August 31, 2010
Study Completion Date
August 31, 2010
deferasirox:
Participants were administered daily with deferasirox starting dose of 20 mg/kg orally to a maximum dose of 40 mg/kg/day.
New York Presbyterian Hospital, New York
New York Medical College, Valhalla
Schneider Children's Hospital, New Hyde Park
Penn State Children's Hospital, Hershey
St Christopher's Hospital for Children, Philadelphia
University of Maryland Greenebaum Cancer Center, Baltimore
Wake Forest University Health Sciences, Winston-Salem
Medical College of Georgia, Augusta
Children's Memorial, Chicago
Washington University School of Medicine, St Louis
Tulane University Health Sciences Center, New Orleans
University of Oklahoma, Oklahoma City
Texas Children's Cancer Center and Hematology Services, Houston
University of Colorado Denver, Colorado Sickle Cell Treatment and Research Center, Aurora
Bay Area Cancer Research Group, Pleasant Hill
Children's Hospital and Research Center, Oakland
Stanford University, Palo Alto
Yale University School of Medicine, New Haven
Children's Hospital of Boston, Boston
Boston Medical Center, Boston
The Cancer Center at Hackensack University Medical Center, Hackensack
Cancer Institute of New Jersey, New Brunswick
St Joseph Children's Hospital, Paterson
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY